[HTML][HTML] Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label …

S McCormack, DT Dunn, M Desai, DI Dolling, M Gafos… - The Lancet, 2016 - thelancet.com
Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, …

[HTML][HTML] The impact of economic crises on communicable disease transmission and control: a systematic review of the evidence

M Suhrcke, D Stuckler, JE Suk, M Desai, M Senek… - PloS one, 2011 - journals.plos.org
There is concern among public health professionals that the current economic downturn,
initiated by the financial crisis that started in 2007, could precipitate the transmission of …

[HTML][HTML] Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

…, R Byrne, R Chilvers, S Coelho, S Day, M Desai… - …, 2022 - thelancet.com
Background Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel
technology formulated as a low dose vaccine against COVID-19. Methods A phase I first-in-…

[HTML][HTML] Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

…, AM Young, JR Havens, VD Hope, M Desai… - The Lancet Infectious …, 2018 - thelancet.com
Background People who inject drugs (PWID) experience a high prevalence of incarceration
and might be at high risk of HIV and hepatitis C virus (HCV) infection during or after …

Sexualised drug use in the United Kingdom (UK): A review of the literature

…, V Hope, H Mohammed, M White, M Desai - International Journal of …, 2018 - Elsevier
Background Sexualised drug use (SDU) refers to the use of drugs in a sexual context. This
includes ‘Chemsex’- the use of drugs (specifically crystal methamphetamine, GHB/GBL and …

Recent advances in pre-exposure prophylaxis for HIV

M Desai, N Field, R Grant, S McCormack - Bmj, 2017 - bmj.com
Although pre-exposure prophylaxis (PrEP)—the use of antiretroviral drugs by non-infected
people to prevent the acquisition of HIV—is a promising preventive option, important public …

[HTML][HTML] Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic …

…, KJ Ong, ON Gill, A Nardone, M Desai… - The Lancet infectious …, 2018 - thelancet.com
Background In the UK, HIV incidence among men who have sex with men (MSM) has remained
high for several years, despite widespread use of antiretroviral therapy and high rates of …

BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018

…, D Asboe, V Cambiano, D Clutterbuck, M Desai… - HIV …, 2019 - discovery.ucl.ac.uk
We aim to provide evidence-based guidance on best clinical practice in the provision,
monitoring and support of pre-exposure prophylaxis (PrEP) for the prevention of HIV acquisition. …

[HTML][HTML] An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis

DI Dolling, M Desai, A McOwan, R Gilson, A Clarke… - Trials, 2016 - Springer
Background Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the
sexual acquisition of the human immunodeficiency virus (HIV). The PROUD study found that …

Genetic counseling and testing in African American patients with breast cancer: a nationwide survey of US breast oncologists

…, AJ Housten, AA Baumann, M Desai… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE To determine if physicians' self-reported knowledge, attitudes, and practices
regarding genetic counseling and testing (GCT) vary by patients' race. METHODS We conducted …